339 results
8-K
EX-99.1
NKTR
Nektar Therapeutics
8 Aug 24
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
4:20pm
of facilities costs allocated to research and development expenses partially offset by a decrease in employee costs.
Non-cash restructuring and impairment … -0165, and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue
424B3
NKTR
Nektar Therapeutics
5 Jun 24
Prospectus supplement
5:30pm
depress the market for our common stock. We expect to continue incurring costs associated with research and development with respect to our programs … and our future research and development plans;
any statements regarding the timing for the start or end of clinical trials or submission of regulatory
8-K
EX-99.1
NKTR
Nektar Therapeutics
9 May 24
Nektar Therapeutics Reports First Quarter 2024 Financial Results
4:20pm
and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin and NKTR-0165 … are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety
8-K
EX-99.1
3fco5h
4 Mar 24
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
4:20pm
8-K
EX-99.1
f7c37yj8xu
7 Nov 23
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
4:21pm
8-K
EX-99.1
8yca2ffwup j51qo
8 Aug 23
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.2
vhwa51 fg68
7 Aug 23
Regulation FD Disclosure
6:40am
8-K
EX-99.1
qhklpw
9 May 23
Nektar Therapeutics Reports First Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
jlog0kdxuk ovzazq
27 Apr 23
Termination of a Material Definitive Agreement
8:40am
8-K
EX-99.1
vdehyesxc6itl
17 Apr 23
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
5:19pm